Legend IPO, China reliance, Harbour-Mount Sinai—FiercePharmaAsia by Angus Liu Friday, March 13, 2020 J&J CAR-T partner Legend aims for U.S. IPO. The FDA's not sure how many drugs and APIs come from China. Harbour teams with Mount Sinai on coronavirus.
PhRMA locks down D.C. office after contact with COVID-19 patient by Kyle Blankenship Tuesday, March 10, 2020 As drugmakers lock down in response to the coronavirus outbreak, pharma's top trade group has had a scare of its own at its Washington, D.C., office.
Takeda's Ninlaro swings and misses in newly diagnosed myeloma by Carly Helfand Tuesday, March 10, 2020 Just a day after BMS said Empliciti had failed a multiple myeloma trial that could have widened its market, Takeda revealed Ninlaro had done the same.
India export, Roche's Actemra, Takeda and more—FiercePharmaAsia by Angus Liu Friday, March 6, 2020 India curbs export of 26 active ingredients and drugs. China uses Roche's Actemra against COVID-19. Takeda nets $940 million through asset sales.
Takeda sells U.S. HQ, Latam brands for $940M by Angus Liu Monday, March 2, 2020 Takeda's offloading 18 Latin American brands for $825 million and just closed on the $115 million sale of its old U.S. HQ in Chicago suburbs.
Harvard-GIRH, GSK-Clover, Vir-WuXi and more—FiercePharmaAsia by Angus Liu Friday, February 28, 2020 Several influential institutions and biopharma companies have joined hands in developing COVID-19 therapies. Takeda's buying PvP for $330 million.
Spark, Ipsen and more join Rare Disease Day 2020 efforts by Beth Snyder Bulik Friday, February 28, 2020 Rare Disease Day is always the last day of February, but this year the date falls on the quadrennial-only Feb. 29, making the day truly rare.
Takeda highlights rare disease with 'Number 17' campaign by Beth Snyder Bulik Friday, February 28, 2020 Seventeen rare disease patients are the faces of the Takeda’s awareness campaign leading up to Rare Disease Day on Saturday, Feb. 29.
Coronavirus, AZ, vadadustat and more—FiercePharmaAsia by Angus Liu Friday, February 21, 2020 AZ expects COVID-19 to slow its growth. Health regulators warn of potential drug shortages. Akebia will use a priority review voucher on vadadustat.
Takeda CEO: World must be 'more proactive' on outbreak prep by Eric Sagonowsky Thursday, February 20, 2020 The scientific community has again been caught off guard and industry officials are talking about implementing better preventive measures.
